This plain language summary describes the results of a study called ATTR-ACT, which was published in the American Journal of Cardiology. In ATTR-ACT, researchers looked at the effects of tafamidis treatment in people with transthyretin amyloid cardiomyopathy. This summary is intended to help people with ATTR-CM and caregivers understand the disease, its treatment, and results
from ATTR-ACT.
Read the full article here.
The original article, called ‘Impact of Tafamidis on Health-Related Quality of Life in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)’ was published in the American Journal of Cardiology and can be read here.